JP7767301B2 - チロシン受容体キナーゼ阻害剤を調製する方法 - Google Patents

チロシン受容体キナーゼ阻害剤を調製する方法

Info

Publication number
JP7767301B2
JP7767301B2 JP2022559980A JP2022559980A JP7767301B2 JP 7767301 B2 JP7767301 B2 JP 7767301B2 JP 2022559980 A JP2022559980 A JP 2022559980A JP 2022559980 A JP2022559980 A JP 2022559980A JP 7767301 B2 JP7767301 B2 JP 7767301B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
formula
hydrogen
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522841A (ja
JP2023522841A5 (https=
Inventor
コロル パル
プラサント デブ
ハリ プラカシュ
アヴィナシュ ボルデ
Original Assignee
ピラミッド バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピラミッド バイオサイエンシズ インコーポレイテッド filed Critical ピラミッド バイオサイエンシズ インコーポレイテッド
Publication of JP2023522841A publication Critical patent/JP2023522841A/ja
Publication of JP2023522841A5 publication Critical patent/JP2023522841A5/ja
Application granted granted Critical
Publication of JP7767301B2 publication Critical patent/JP7767301B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022559980A 2020-04-15 2021-04-15 チロシン受容体キナーゼ阻害剤を調製する方法 Active JP7767301B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010108P 2020-04-15 2020-04-15
US63/010,108 2020-04-15
PCT/US2021/027538 WO2021211882A1 (en) 2020-04-15 2021-04-15 Methods for preparing tyrosine receptor kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2023522841A JP2023522841A (ja) 2023-06-01
JP2023522841A5 JP2023522841A5 (https=) 2024-04-26
JP7767301B2 true JP7767301B2 (ja) 2025-11-11

Family

ID=78083713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559980A Active JP7767301B2 (ja) 2020-04-15 2021-04-15 チロシン受容体キナーゼ阻害剤を調製する方法

Country Status (12)

Country Link
US (1) US12606565B2 (https=)
EP (1) EP4135700A4 (https=)
JP (1) JP7767301B2 (https=)
KR (1) KR20230011912A (https=)
CN (1) CN115515591B (https=)
AU (1) AU2021255613A1 (https=)
BR (1) BR112022020114A2 (https=)
CA (1) CA3172681A1 (https=)
IL (1) IL296921A (https=)
MX (1) MX2022012437A (https=)
WO (1) WO2021211882A1 (https=)
ZA (1) ZA202209792B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202005237SA (en) 2017-12-15 2020-07-29 Pyramid Biosciences Inc 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
IL296921A (en) 2020-04-15 2022-12-01 Pyramid Biosciences Inc Methods for making receptor tyrosine kinase inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
JP2014520898A (ja) 2011-07-21 2014-08-25 トレロ ファーマシューティカルズ， インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
JP2017538766A (ja) 2014-12-15 2017-12-28 シーエムジー ファーマシューティカル カンパニー，リミテッド 縮合環ヘテロアリール化合物及びｔｒｋ抑制剤としての用途
JP2018500376A (ja) 2014-12-30 2018-01-11 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害薬としてのピロロ及びピラゾロピリミジン
WO2019118584A1 (en) 2017-12-15 2019-06-20 Pyramid Biosciences, Inc. 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CN101242844A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 作为激酶调节剂的氨基嘧啶类化合物
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
KR101324804B1 (ko) 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
WO2014055928A2 (en) * 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
FR3029769A1 (fr) 2014-12-10 2016-06-17 Tornier Sa Kit pour une prothese d'epaule
JP6475084B2 (ja) 2015-05-21 2019-02-27 臼井国際産業株式会社 トルクセンサ用シャフトの製造設備およびその製造方法
WO2018005533A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
IL296921A (en) 2020-04-15 2022-12-01 Pyramid Biosciences Inc Methods for making receptor tyrosine kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
JP2014520898A (ja) 2011-07-21 2014-08-25 トレロ ファーマシューティカルズ， インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
JP2017538766A (ja) 2014-12-15 2017-12-28 シーエムジー ファーマシューティカル カンパニー，リミテッド 縮合環ヘテロアリール化合物及びｔｒｋ抑制剤としての用途
JP2018500376A (ja) 2014-12-30 2018-01-11 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害薬としてのピロロ及びピラゾロピリミジン
WO2019118584A1 (en) 2017-12-15 2019-06-20 Pyramid Biosciences, Inc. 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PubChem CID 64179089，2012年10月23日
Tetrahedron，2007年，63(3)，p.748-753

Also Published As

Publication number Publication date
CA3172681A1 (en) 2021-10-21
WO2021211882A1 (en) 2021-10-21
EP4135700A4 (en) 2024-04-17
KR20230011912A (ko) 2023-01-25
US12606565B2 (en) 2026-04-21
US20230242536A1 (en) 2023-08-03
JP2023522841A (ja) 2023-06-01
AU2021255613A1 (en) 2022-09-29
CN115515591A (zh) 2022-12-23
EP4135700A1 (en) 2023-02-22
IL296921A (en) 2022-12-01
MX2022012437A (es) 2022-10-27
CN115515591B (zh) 2024-09-27
BR112022020114A2 (pt) 2022-11-29
ZA202209792B (en) 2025-01-29

Similar Documents

Publication Publication Date Title
AU2022202494B2 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
AU2017376629B2 (en) Benzimidazole compounds as c-Kit inhibitors
WO2021244659A1 (zh) 同位素取代的螺芳环化合物及其应用
JP7425724B2 (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体
TWI848925B (zh) 肌旋蛋白激酶抑制劑
CN110291086A (zh) 作为c-kit抑制剂的氨基噻唑化合物
AU2011288876A2 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
WO2009059272A1 (en) Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
JP2021529182A (ja) Ｔｒｋ阻害剤としてのヘテロ環化合物
JP7767301B2 (ja) チロシン受容体キナーゼ阻害剤を調製する方法
JP2019512533A (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
CN110099906A (zh) 作为激酶抑制剂的酰胺化合物
CN104903326B (zh) 被取代的吡唑并[3,4‑D]嘧啶化合物、其制备及作为σ受体配体的用途
JP2024542221A (ja) １５－ｐｇｄｈ阻害剤及び使用
JP2021011492A (ja) ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物
RU2781100C1 (ru) Соединения со спиро- и ароматическими кольцами и их применение
WO2026019442A1 (en) Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors
WO2026019918A1 (en) Compositions useful for modulating splicing
HK40046916B (zh) 作为激酶抑制剂的酰胺化合物、组合物和治疗方法
NZ795575A (en) Benzimidazole compounds as c-Kit inhibitors

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251020

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251029

R150 Certificate of patent or registration of utility model

Ref document number: 7767301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150